Grant: Discovery Grants Program - Individual
University of Guelph
$33,000.00
Molecular Phylogenetics, Diagnostics and Control of Apicomplexan Parasites
FY 2016-17
Summary
The
long term goal of my research program is to explore and understand the interactions between
parasites of the phylum Apicomplexa and their hosts at the historical,
organismal (host-parasite) and molecular levels. These parasites cause
important animal and human diseases such as malaria, toxoplasmosis,
cryptosporidiosis and coccidiosis. I propose to further our understanding of
these relationships by pursuing three main areas of study:
1) Investigate apicomplexan phylogeny and host-parasite coevolution
using multi genome molecular markers with morphological and morphometric
characters: We will determine the biodiversity of apicomplexan parasites in
humans, domesticated animals and wildlife (potential zoonotics) by generating
sequence data (nuclear 18S rDNA, plastid rDNA/polymerase B, and mt cytochrome c oxidase subunit I, COI) from
apicomplexan parasites that infect both domestic and, largely ignored, wildlife
hosts. Our newly developed PCR primer pairs will generate species-specific
COI-based DNA barcodes that will be used to identify specifically coccidia
(Eimeriorina) including enteric (e.g. Eimeria)
and tissue (e.g. Toxoplasma)
coccidia. We will modify our DNA barcode primers for use in a multiplexed NGS
assay to both identify and enumerate mixed coccidia in biological samples such
as fecal or tissue samples; this method will permit rapid protistan parasite
biodiversity and species discovery;
2)
Generate complete mitochondrial (mt) genomes from biologically diverse
apicomplexan parasites to explore the structural evolution of mt genomes and
generate sequence data necessary for inferring the evolutionary history of
these cosmopolitan parasites.
3) Explore immunological control of coccidia of domestic poultry. We
will determine
the natural prevalence of Eimeria that infect domestic turkeys
nationally and internationally to determine the number of species required in a
multivalent live coccidiosis vaccine against turkey coccidiosis. We will refine and further develop a recombinant
multivalent vaccine technology that combines two parasite antigenic epitopes with a
host-derived immune modulating epitope (HMGB1).
The current Bacillus subtilis expression vector for this multivalent
vaccine construct will be converted into a strictly peptide based (i.e.
chemically synthesized) form and tested for biological activity in vivo when
delivered by various means. Successful
vaccination against Eimeria species using a non-viable vaccine construct (a
global first) would address vaccine production, transportation and shelf life
issues as well as avoid health implications of using live coccidiosis vaccines
in commercial poultry.
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2016-05826
Name nom
Barta, John
Department département
Pathobiology - Pathobiology
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
33000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5203
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Protozoology
Research subject fr
Protozoologie
Partie
1
Nb partie
5
Application title
Molecular Phylogenetics, Diagnostics and Control of Apicomplexan Parasites
Keyword
NSERC
Application summary
The
long term goal of my research program is to explore and understand the interactions between
parasites of the phylum Apicomplexa and their hosts at the historical,
organismal (host-parasite) and molecular levels. These parasites cause
important animal and human diseases such as malaria, toxoplasmosis,
cryptosporidiosis and coccidiosis. I propose to further our understanding of
these relationships by pursuing three main areas of study:
1) Investigate apicomplexan phylogeny and host-parasite coevolution
using multi genome molecular markers with morphological and morphometric
characters: We will determine the biodiversity of apicomplexan parasites in
humans, domesticated animals and wildlife (potential zoonotics) by generating
sequence data (nuclear 18S rDNA, plastid rDNA/polymerase B, and mt cytochrome c oxidase subunit I, COI) from
apicomplexan parasites that infect both domestic and, largely ignored, wildlife
hosts. Our newly developed PCR primer pairs will generate species-specific
COI-based DNA barcodes that will be used to identify specifically coccidia
(Eimeriorina) including enteric (e.g. Eimeria)
and tissue (e.g. Toxoplasma)
coccidia. We will modify our DNA barcode primers for use in a multiplexed NGS
assay to both identify and enumerate mixed coccidia in biological samples such
as fecal or tissue samples; this method will permit rapid protistan parasite
biodiversity and species discovery;
2)
Generate complete mitochondrial (mt) genomes from biologically diverse
apicomplexan parasites to explore the structural evolution of mt genomes and
generate sequence data necessary for inferring the evolutionary history of
these cosmopolitan parasites.
3) Explore immunological control of coccidia of domestic poultry. We
will determine
the natural prevalence of Eimeria that infect domestic turkeys
nationally and internationally to determine the number of species required in a
multivalent live coccidiosis vaccine against turkey coccidiosis. We will refine and further develop a recombinant
multivalent vaccine technology that combines two parasite antigenic epitopes with a
host-derived immune modulating epitope (HMGB1).
The current Bacillus subtilis expression vector for this multivalent
vaccine construct will be converted into a strictly peptide based (i.e.
chemically synthesized) form and tested for biological activity in vivo when
delivered by various means. Successful
vaccination against Eimeria species using a non-viable vaccine construct (a
global first) would address vaccine production, transportation and shelf life
issues as well as avoid health implications of using live coccidiosis vaccines
in commercial poultry.